Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In A Changing Diabetes Drug Market, Who Will Come Out On Top?

Executive Summary

New treatments for Type 2 diabetes are driving the optimism underlying Bristol and AstraZeneca’s proposed acquisition for Amylin and are leading to a re-alignment of allies and competitors focused on the disease. Companies are enthusiastic about the vast opportunity, yet worried about the costs and risks of full-scale commitment to it.

You may also be interested in...



Diabetes Is Not For The Faint Of Heart

Regulatory and commercial hurdles in the type 2 diabetes market have created a space where only the largest, most sophisticated companies can expect to compete.

Diabetes Is Not For The Faint Of Heart

Regulatory and commercial hurdles in the type 2 diabetes market have created a space where only the largest, most sophisticated companies can expect to compete.

Takeda’s Hat Trick Marks The First New Molecular Entity Of 2013

Takeda’s type 2 diabetes drug alogliptin – on its third pass through FDA – was cleared Jan. 25 as a single agent as Nesina, in combination with metformin as Kazano and in combination with pioglitazone as Oseni.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054581

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel